Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants.

Wu H, Shekar SC, Flinn RJ, El-Sibai M, Jaiswal BS, Sen KI, Janakiraman V, Seshagiri S, Gerfen GJ, Girvin ME, Backer JM.

Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20258-63. doi: 10.1073/pnas.0902369106. Epub 2009 Nov 13.

PMID:
19915146
2.

Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.

Huang CH, Mandelker D, Gabelli SB, Amzel LM.

Cell Cycle. 2008 May 1;7(9):1151-6. Epub 2008 Feb 27. Review.

PMID:
18418043
3.

Human tumor mutants in the p110alpha subunit of PI3K.

Liu Z, Roberts TM.

Cell Cycle. 2006 Apr;5(7):675-7. Epub 2006 Apr 1. Review.

PMID:
16627990
4.

Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.

Hao Y, Zhao S, Wang Z.

Toxicol Pathol. 2014 Jan;42(1):140-7. doi: 10.1177/0192623313506794. Epub 2013 Oct 31. Review.

PMID:
24178578
5.

A beta version of life: p110β takes center stage.

Dbouk HA, Backer JM.

Oncotarget. 2010 Dec;1(8):729-33. Review.

PMID:
21321382
6.

The regulation of class IA PI 3-kinases by inter-subunit interactions.

Backer JM.

Curr Top Microbiol Immunol. 2010;346:87-114. doi: 10.1007/82_2010_52. Review.

PMID:
20544340
7.

Class I PI3K in oncogenic cellular transformation.

Zhao L, Vogt PK.

Oncogene. 2008 Sep 18;27(41):5486-96. doi: 10.1038/onc.2008.244. Review.

PMID:
18794883
8.

Regulation of class IA PI3Ks: is there a role for monomeric PI3K subunits?

Geering B, Cutillas PR, Vanhaesebroeck B.

Biochem Soc Trans. 2007 Apr;35(Pt 2):199-203. Review.

PMID:
17371237
9.

Phosphatidylinositol 3-kinase: the oncoprotein.

Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, Zhao L, Denley A.

Curr Top Microbiol Immunol. 2010;347:79-104. doi: 10.1007/82_2010_80. Review.

PMID:
20582532
10.

Mutated PI 3-kinases: cancer targets on a silver platter.

Kang S, Bader AG, Zhao L, Vogt PK.

Cell Cycle. 2005 Apr;4(4):578-81. Epub 2005 Apr 7. Review.

PMID:
15876869
11.

Structural effects of oncogenic PI3Kα mutations.

Gabelli SB, Huang CH, Mandelker D, Schmidt-Kittler O, Vogelstein B, Amzel LM.

Curr Top Microbiol Immunol. 2010;347:43-53. doi: 10.1007/82_2010_53. Review.

PMID:
20593314
12.

Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase.

Gabelli SB, Duong-Ly KC, Brower ET, Amzel LM.

Adv Enzyme Regul. 2011;51(1):273-9. doi: 10.1016/j.advenzreg.2010.09.013. Epub 2010 Oct 28. Review.

PMID:
21035489
13.

The structural basis of PI3K cancer mutations: from mechanism to therapy.

Liu S, Knapp S, Ahmed AA.

Cancer Res. 2014 Feb 1;74(3):641-6. doi: 10.1158/0008-5472.CAN-13-2319. Epub 2014 Jan 23. Review.

PMID:
24459181

Supplemental Content

Support Center